High levels of catalytic antibodies correlate with favorable outcome in sepsis by Lacroix-Desmazes, Sebastien et al.
High levels of catalytic antibodies correlate with
favorable outcome in sepsis
Se´bastien Lacroix-Desmazes*†, Jagadeesh Bayry*, Srini V. Kaveri*, David Hayon-Sonsino‡, Nithyananda Thorenoor*,
Julien Charpentier‡, Charles-Edouard Luyt‡, Jean-Paul Mira‡§, Valakunja Nagaraja¶, Michel D. Kazatchkine*,
Jean-Franc¸ois Dhainaut‡, and Vincent O. Mallet‡
*Institut National de la Sante´ et de la Recherche Me´dicale, Unite 681, Universite´ Paris VI, Institut des Cordeliers, 15 Rue de l’Ecole de Me´decine, 75006 Paris,
France; ‡Department of Medical Intensive Care, Hoˆpital Universitaire Cochin-Port Royal, Assistance Publique-Hoˆpitaux de Paris, Universite´ Paris V, 27 Rue du
Faubourg Saint Jacques, 75014 Paris, France; §Institut National de la Sante´ et de la Recherche Me´dicale, Unite 567, Institut Cochin, 27 Rue du Faubourg Saint
Jacques, 75014 Paris, France; and ¶Indian Institute of Science, Bangalore 560 012, India
Communicated by Michael Sela, Weizmann Institute of Science, Rehovot, Israel, January 24, 2005 (received for review October 24, 2004)
Sepsis is the leading cause of death in intensive care units and
results from a deleterious systemic host response to infection.
Although initially perceived as potentially deleterious, catalytic
antibodies have been proposed to participate in removal of met-
abolic wastes and protection against infection. Here we show that
the presence in plasma of IgG endowed with serine protease-like
hydrolytic activity strongly correlates with survival from sepsis.
Variances of catalytic rates of IgG were greater in the case of
patients with severe sepsis than healthy donors (P < 0.001),
indicating that sepsis is associated with alterations in plasma levels
of hydrolytic IgG. The catalytic rates of IgG from patients who
survived were significantly greater than those of IgG from de-
ceased patients (P < 0.05). The cumulative rate of survival was
higher among patients exhibiting high rates of IgG-mediated
hydrolysis as compared with patients with low hydrolytic rates
(P < 0.05). An inverse correlation was also observed between the
markers of severity of disseminated intravascular coagulation and
rates of hydrolysis of patients’ IgG. Furthermore, IgG from three
surviving patients hydrolyzed factor VIII, one of which also hydro-
lyzed factor IX, suggesting that, in some patients, catalytic IgG may
participate in the control of disseminated microvascular thrombo-
sis. Our observations provide the first evidence that hydrolytic
antibodies might play a role in recovery from a disease.
The initial host response to infection relies on cellular andmolecular effectors of the innate immune system. The rec-
ognition of pathogen-associated molecular patterns stimulates
the production of proinflammatory cytokines such as tumor
necrosis factor , and activates components of the complement
cascade (1). Natural antibodies, which represent the spontane-
ous repertoire of circulating immunoglobulins in healthy unim-
munized individuals, are part of the innate immune system; they
promote the clearance of pathogenic substances from the cir-
culation and prevent pathogen dissemination (2, 3). The inability
to regulate the inflammatory response initiated upon infection
leads to severe sepsis that is characterized by widespread mi-
crovascular injury and thrombosis, organ ischemia, and dysfunc-
tion (4).
Catalytic antibodies are immunoglobulins endowed with a
capacity to hydrolyze an antigenic substrate. Catalytic antibodies
have mostly been reported in diverse pathological states, includ-
ing autoimmunity, alloimmune and inflammatory disorders, and
viral infections (5–9). Although there is evidence supporting a
pathogenic role for factor VIII-hydrolyzing antibodies in inhib-
itor-positive patients with hemophilia A and for a subset of
platelet-fragmenting antibodies in HIV infection (8, 10), the
deleterious role of catalytic antibodies in the other disorders
remains debated. Catalytic antibodies of the IgG and IgM
isotypes are also part of naturally occurring antibodies (11, 12)
and are suggested to participate in the removal of metabolic
wastes and protect from bacterial infections (13–15). We hy-
pothesized that catalytic antibodies may limit infection and
inflammation in patients with sepsis, and, conversely, that the
lack of a catalytic antibody response may hasten pathogenesis.
Materials and Methods
Patients. Plasma from 34 consecutive patients diagnosed with
severe sepsis (9 of 34) or septic shock (25 of 34) for 24 h, was
obtained from the Department of Medical Intensive Care,
Hoˆpital Cochin, Paris, under approval by the local ethic board on
human subject research. Patients were 17–81 years old (median,
53.5 years) with a 16:18 malefemale ratio. Seventeen patients
had no underlying disease. Twenty-two patients presented with
pneumonia, three presented with urosepsis, two presented with
osteoarthritis, two presented with intraabdominal infection, two
presented with liver abscess, two presented with bloodborn
infection, and one presented with meningitis. The simplified
acute physiology score II (SAPS II) and the sequential organ
failure assessment (SOFA) score were recorded on the day of
diagnosis. The median SAPS II was 40.5, and the median SOFA
was 7. Twenty-three patients had at least two dysfunctional
organs or systems, and 18 required mechanical ventilation.
Patients had equal incidence of Gram-positive and -negative
infections. All patients received standard medical care and daily
clinical and laboratory data were recorded. Ten patients (29.4%)
died within the 28 days after admission. The activated partial
thromboplastin time (aPTT) and prothrombin time (PT) were
determined as described (16). aPTT is expressed as the ratio of
the scored value to a reference value. PT is expressed as the
percentage of the clotting time measured with reference to a
standard plasma. Plasma from 10 healthy blood donors and a
therapeutic preparation of i.v. immunoglobulins (IVIg, ZLB
Behring, Bern, Switzerland) were used as sources of control IgG.
Purification of IgG. IgG was isolated from plasma by chromatogra-
phy on protein G-Sepharose, followed by immediate size-exclusion
chromatography on a superose-12 column equilibrated with 50mM
Tris, 8 M urea, and 0.02% NaN3, pH 7.7. IgG-containing fractions
were pooled and dialyzed against 50 mM Tris100 mM glycine
0.02% NaN3, pH 7.7, at 4°C. The purity of IgG preparations was
assessed by SDSPAGE and immunoblot. IgG was quantified by
ELISA. The purification procedure makes it unlikely that the
hydrolysis is caused by contaminating proteases.
Hydrolysis of Proline-Phenylalanine-Arginine-Methylcoumarinamide
(PFR-MCA). To assess their catalytic activity, IgG antibodies (13.3
nM) were mixed with proline-phenylalanine-arginine-methyl-
Abbreviations: SAPS II, simplified acute physiology score II; SOFA, sequential organ failure
assessment; PT, prothrombin time; aPTT, activated partial thromboplastin time; PFR-MCA,
proline-phenylalanine-arginine-methylcoumarinamide; IVIg, i.v. immunoglobulins; DIC,
disseminated intravascular coagulation.
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coumarinamide (PFR-MCA, 100 M, Peptide Institute, Osaka)
in 40 l of 50 mM TrisHCl100 mM glycine0.025% Tween
200.02% NaN3, pH 7.7, in white 96-well U-bottomed plates and
incubated in the dark for 24 h at 37°C. Hydrolysis of the
PFR-MCA substrate was determined as the fluorescence of the
leaving group (aminomethylcoumarin;em, 460 nm,ex, 370 nm)
using a fluoroscan. Fluorescence values were compared to a
standard curve of free MCA, and the corresponding quantities
of released MCA were computed. At each time point, back-
ground release of MCA, measured for each PFR-MCA concen-
tration in wells containing the substrate alone, was subtracted
from the value observed in the presence of the antibodies. Data
are expressed as the quantity of releasedMCA computed at time
0 subtracted from the quantity of released MCA computed at a
given time point, per amount of time per amount of IgG (i.e.,
mol per min per mol). Data presented summarize three to five
separate experiments (interclass correlation coefficient, 0.73).
Hydrolysis of Biotinylated Antigens. Recombinant human factor
VIII (3 nmol, Kogenate II, Bayer), plasma-derived human
albumin (HSA, 5 nmol, Laboratoire Franc¸ais de Fractionnement
et de Biotechnologie, Les Ulis, France), factor IIa (13 nmol,
LFB), and factor IX (2 nmol, BeneFix, Baxter, Deerfield, IL)
were desalted and recovered in 3 ml of borate buffer (100 mM
borate, pH 7.0150 mM NaCl5 mM CaCl2). Biotin (11 g, 25
gml) was allowed to react with each antigen with gentle
agitation in the dark for 2 h at 4°C. Biotinylated antigens were
dialyzed against borate buffer for 2 h at 4°C, aliquoted, and
stored at 20°C until use.
Biotinylated antigens (385 nM) were incubated in 40 l of
catalytic buffer (50 mM TrisHCl, pH 7.7100 mM glycine0.025%
Tween 200.02%NaN3) with the IgG samples (10gml, 66.7 nM)
to be tested for 24 h at 37°C. Samples were mixed with Laemmli’s
buffer without mercaptoethanol (1:1 volvol), and 20 l of each
sample was subjected to SDS10% PAGE. Protein fragments were
then transferred onto nitrocellulose membrane (Schleicher &
Schuell, Keene, NH). After overnight blocking in PBS, 1% BSA
0.1% Tween 20 at 4°C, membranes were incubated with strepta-
vidin-coupled horseradish-peroxidase (Amersham Pharmacia) for
30min at room temperature.After washing in PBS containing 0.1%
Tween 20, labeled proteins were revealed by using the ECL kit
(Amersham Pharmacia) and BIOMAX ML films (Kodak). Films
were scanned by using a SnapScan 600 (Agfa, Mortsel, Belgium)
scanner.
Results
Hydrolytic Activity of IgG from Septic Patients. Plasma was collected
from 34 consecutive septic patients diagnosed for24 hwith severe
sepsis (9 patients) or septic shock (25 patients) (Table 1) (17). IgG
was purified from plasma by affinity chromatography on protein G,
followed by size-exclusion chromatography in the presence of 8 M
urea to ensure the removal of putative contaminating proteases.
The hydrolytic activity of IgG was measured upon incubation with
PFR-MCA, a generic peptidic substrate for serine proteases. IgG
from septic patients was found to hydrolyze PFR-MCAwith amean
hydrolytic activity of 119.6  175.5 molmin per mol (ranging
from 16.3 to 893.1 molmin per mol). The mean hydrolytic
activity of IgG of 10 healthy donors was 60.7 54.4 molmin per
mol (ranging from 19.5 to 199.2 molmin per mol). It was 62.6
25.4 molmin per mol in the case of pooled normal IgG for
therapeutic use (IVIg). Hydrolysis of the PFR-MCA substrate by
IgG of patients and controls was dose- and time-dependent (data
not shown).
Purified IgG from 9 of the 34 septic patients exhibited catalytic
activities greater than the mean catalytic activity of IVIg 2 SD
(i.e., 113.5 molmin per mol), whereas IgG from only 1 of 10
healthy controls exhibited such high catalytic activity (Fig. 1).
The variances of catalytic rates of IgG were greater in the case
of patients than healthy controls (F test, P  0.001), indicating
that sepsis is associated with alterations in plasma levels of
hydrolytic IgG. Rates of IgG-mediated hydrolysis were not
related to the nature of the infecting organism nor to that of the
underlying medical condition.
HighRatesofIgG-MediatedHydrolysisCorrelatewithSurvival.Twenty-
four of the 34 patients included in the study (70.6%) were alive
28 days after admission. The rates of PFR-MCA hydrolysis by
IgG of patients who survived sepsis were significantly greater
than those of IgG of deceased patients (Fig. 1, Mann–Whitney
U test, P  0.05). The 34 patients of the study were then ranked
according to IgG hydrolysis rates and divided into two groups
based on the median catalytic activity of IgG. The cumulative
rate of survival over a period of 28 days was significantly higher
among patients exhibiting high rates of IgG-mediated hydrolysis
as compared with patients with low hydrolytic rates of IgG (Fig.
2, Kaplan–Meier analysis, P  0.05). Dividing the patients into
quartiles and calculating the odd risk (OR) ratio for each
quartile, confirmed that high rates of PFR-MCA hydrolysis
correlate with increased survival from sepsis (Fig. 3). In line with
these observations, there was an inverse relationship between
the rates of PFR-MCA hydrolysis by patients’ IgG and the
severity of the disease as assessed by the SAPS II score (Spear-
man’s rank correlation test, P  0.002), the requirement for
vasopressive drugs (P  0.05) and the levels of plasma lactate
(P 0.05), as well as organ dysfunction assessed by means of the
SOFA score (P  0.001).
Correlation of IgG-Mediated Hydrolysis with Markers of Disseminated
Intravascular Coagulation (DIC). Sepsis is characterized by DIC that
involves the generation of intravascular fibrin and the consump-
Table 1. Clinical characteristics of patients with sepsis (n  34)
Age, median (25th, 75th percentile) 53.5 (47, 72.5)
Male sex, n (%) 16 (47.1)
Prior or preexisting conditions, n (%)
Hypertension 5 (14.7)
Congestive cardiomyopathy 2 (5.9)
Diabetes 3 (8.8)
Cirrhosis 5 (14.7)
Chronic obstructive pulmonary disease 5 (14.7)
Cancer 1 (2.9)
Immunosuppression 7 (20.6)
Type of patient, n (%)
Medical 32 (94.1)
Elective surgery 1 (2.9)
Emergency surgery 1 (2.9)
Infecting organism, n (%)
Gram-positive 12 (35.3)
Gram-negative 10 (29.4)
Mixed 4 (8.9)
Undiagnosed 8 (11.8)
SAPS II, median (25th, 75th percentile) 40.5 (32.8, 53.3)
SOFA, median (25th, 75th percentile) 7 (6, 10)
No. of dysfunctional organs or systems (%)
0 0
1 11 (32.4)
2 14 (41.2)
3 5 (14.7)
4 4 (11.7)
Mechanical ventilation, n (%) 18 (52.9)
Use of any vasopressor, n (%) 25 (73.5)
Use of epinephrine or norepinephrine, n (%) 13 (38.2)
The SAPS II ranges from 0 to 174 with higher scores indicating more severe
disease. The SOFA ranges from 0 to 24.
4110  www.pnas.orgcgidoi10.1073pnas.0500586102 Lacroix-Desmazes et al.
tion of procoagulants and platelets. Interestingly, the PT, de-
termined for each patient at the time of diagnosis of sepsis,
exhibited a significant correlation with the hydrolysis rates of
patients’ IgG (P  0.05, Fig. 3), whereas the aPTT and platelet
counts displayed tendencies for significant correlation with rates
of PFR-MCA hydrolysis (P  0.1 in both cases; Fig. 3 and data
not shown). We and others have demonstrated that catalytic IgG
may inactivate factor VIII in patients with hemophilia A and
activate prothrombin (factor II) in patients with Bence–Jones
proteins (9, 18). Therefore, we tested the hydrolytic activity of
patients’ IgG toward several proteins of potential relevance to
DIC in sepsis. IgG of three of the surviving patients exhibited
hydrolyzing activity toward factor VIII, and IgG from one
patient in this group also cleaved factor IX (Fig. 4). None of the
IgG from deceased patients hydrolyzed procoagulant molecules.
Factor II and HSA were not hydrolyzed by patients’ IgG (data
not shown).
Discussion
We investigated the prevalence of catalytic antibodies in patients
with severe sepsis and septic shock. We observed a high prev-
alence of catalytic IgG in the plasma of septic patients. Anti-
bodies with serine protease-like activity were associated with a
favorable outcome. This finding indicates that catalytic antibod-
ies may be associated with the recovery from a disease.
The catalytic activity of IgG was detected as the cleavage of the
peptide PFR-MCA, a generic synthetic substrate for kallikrein-like
serine proteases. PFR-MCA and related synthetic substrates have
extensively been used in the past to screen for the presence of
human catalytic antibodies because the latter display selectivity for
cleavage at bonds containing basic amino acids (11, 18–21).We and
others have documented that the catalytic activity of IgG is medi-
ated by the F(ab)2 fragments of the antibodies and that it is not
inhibited by a broad range of generic protease inhibitors (7, 9, 18).
In the present study, the purification of IgGonproteinG-Sepharose
immediately followed by size-exclusion chromatography in 8 M
urea further excluded the possibility that PFR-MCA hydrolysis was
mediated by contaminating proteases.
The pathophysiological relevance of catalytic antibodies re-
mains unclear. Catalytic antibodies have mostly been reported in
pathological states, including asthma, alloimmune immunization
to factor VIII in hemophilia A, Hashimoto’s thyroiditis, systemic
lupus erythematosus, scleroderma, rheumatoid arthritis, multi-
ple sclerosis, and HIV-related immune thrombocytopenia (5–9,
22–26). However, with the exceptions of factor VIII-hydrolyzing
IgG in hemophilia and platelet fragmentation caused by anti-
body-induced generation of H2O2 in HIV infection, the delete-
rious role of catalytic antibodies has not been convincingly
Fig. 1. Hydrolytic activity of IgG from septic patients. IgG was purified from
plasma of 34 septic patients (circles) and 10 healthy donors (squares). Ten
patients died within 28 days after diagnosis (filled circles), and 24 patients
survived (open circles). To measure hydrolytic activity, IgG was incubated with
PFR-MCA and fluorescence of released MCA quantitated. Spontaneous hy-
drolysis that occurred upon incubation of PFR-MCA in buffer alone was
subtracted in all cases, thus yielding some negative values.*, Patients’ IgG with
rates greater than the mean catalytic activity of IVIg  2 SD (i.e., 113.5
molmin per mol).
Fig. 2. High rates of IgG-mediated hydrolysis correlate with survival. Patients
with sepsis were ranked according to the rates of hydrolysis of PFR-MCA
exhibited by IgG purified from their plasma and divided into two groups based
on the median catalytic activity of IgG. Cumulative rates of survival of patients
with low catalytic rates (dotted line curve) differed significantly from those of
patients with high catalytic rates (full line curve), as assessed in a Kaplan–Meier
analysis (log-rank test, P  0.05).
Fig. 3. Correlation of rates of IgG-mediated hydrolysis with markers of
disseminated intravascular coagulation. The patients were ranked according
to the rates of IgG-mediated PFR-MCA hydrolysis and grouped into quartiles.
Odd risk (OR) ratios were calculated for each quartile as the number of
deceased patients over that of surviving patients, and are indicated as empty
circles. Mean SEM of the prothrombin time (PT, expressed as the percentage
of the clotting time measured with reference to a standard plasma, empty
bars) and the activated partial thromboplastin time (aPTT, expressed as the
ratio of the scored value to a reference value, full bars) as determined at the
time of diagnosis of sepsis, are represented (eight or nine patients per quar-
tile). PT values exhibited a significant correlation with hydrolysis rates of
patients’ IgG (P 0.05, Spearman’s rank correlation test using the ungrouped
data). aPTT values displayed a tendency for significant correlation with rates
of hydrolysis of patients’ IgG (P  0.1).
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demonstrated (8, 10). Thus, it remains unclear whether catalytic
antibodies detected in pathological conditions are actual effec-
tors of the pathogenic immune response or whether their
expression is secondary to the dysregulated homeostasis of the
immune network. Catalytic IgG have been documented in
healthy individuals (21). Antibodies in the milk of healthy
mothers are endowed with protein kinase and DNase activities
(27, 28). Furthermore, as recently reported, the intrinsic ability
of antibodies to convert molecular oxygen into hydrogen per-
oxide and ozone, imparts them with a bactericidal potency (14,
29). In this respect, our data are in line with the hypothesis that
catalytic antibodies play a protective role against infection (13).
Our data suggest that a lack of catalytic antibodies during
sepsis and septic shock may be deleterious. Indeed, 9 of 10
deceased patients had IgG with low catalytic rates at the time
of diagnosis, and the only deceased patient who presented with
high catalytic rates of IgG passed away 13 days after enroll-
ment from invasive aspergillosis, a fungal infection in which
neutrophils and macrophages represent major lines of host
defense and in which antibody-mediated immunity is known
to play a secondary role (30). The inability of some patients to
express higher levels of catalytic antibodies may be related to
the genetic polymorphism of the repertoire of Ig variable
region-encoding genes that characterizes the human popula-
tion. This finding is reminiscent of findings in BALBc and
MRLlpr mice, that have different abilities to produce cata-
lytic antibodies and that use different V genes, after immuni-
zation with phosphonate haptens (31, 32). Alternatively, lower
levels of IgG-mediated hydrolysis may relate to an increased
prevalence of anti-idiotypic antibodies that neutralize autol-
ogous IgG catalysts. Among the 25 patients who survived,
several had rates of IgG-mediated PFR-MCA hydrolysis at the
time of enrollment that were not significantly higher than that
of healthy donors and IVIg. This finding suggests that IgG-
mediated hydrolysis is one among different mechanisms that
may confer protection in sepsis. Indeed, the initial host
response to infection is known to rely on effectors of the innate
immune system, including molecules from the family of Toll-
like receptors (1), from the complemement cascade and
natural antibodies (2, 33).
Sepsis is associated with DIC that results in organ ischemia
and multiorgan dysfunction (4). The administration of activated
protein C, which functions as a proteolytic inhibitor of the
clotting factors V and VIII and is endowed with antithrombotic,
profibrinolytic, and antiinflammatory properties (34), reduces
mortality in patients with severe sepsis (35). Here, we report an
inverse correlation between the markers of severity of DIC (i.e.,
PT) and rates of hydrolysis of PFR-MCA by patients’ IgG, which
points toward a potential antithrombotic implication of catalytic
antibodies in sepsis. Our finding that IgG from three of the
surviving patients hydrolyzed FVIII andor FIX is in line with
this hypothesis. Interestingly, antibodies that hydrolyze proco-
agulant factors have been described in patients with multiple
myeloma and hemophilia A, with a possible outcome on the
hemostatic status of the patients (9, 18).
It is classically admitted that the beneficial effect of antibodies
in sepsis relates to their capacity to activate complement and
opsonize infectious particles (3). We speculate that the catalytic
activity of IgG synergizes with these properties. Whether cata-
lytic antibodies play a direct bactericidal role, participate in the
control of disseminated microvascular thrombosis, andor reg-
ulate inflammation remains to be uncovered. The data further
suggest that manipulation of the catalytic antibody response may
represent a therapeutic approach of sepsis.
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Fig. 4. Hydrolysis of factors IX and VIII by patients’ IgG. Human recombinant factor IX (FIX) and VIII (FVIII) were incubated in the presence of purified IgG for
24 h at 37°C. Migration profiles are shown for 14 representative patients. Mean optical densities of the migration profiles are indicated as arbitrary units (A.U.)
for six surviving patients with high rates of IgG-mediated hydrolysis (thick line curve), four surviving patients with low rates, and four deceased patients (thin
line curves). Coagulation proteins incubated in buffer alone (Ctl) or in the presence of IVIg (data not shown) were used as negative controls. Patients’ IgG
hydrolyzed neither HSA nor prothrombin (data not shown).
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